PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30137220-7	2019	Treatment of hypoxic JEG-3 cells with rosiglitazone resulted in mitochondrial membrane potential increase and a reduction of caspase 9 and caspase 3 activity which is consistent with improved cell survival.	Rosiglitazone	38-51	caspase 3	Homo sapiens	139-148	
16777971-7	2006	Rosiglitazone-induced apoptosis was associated with a decrease of Bcl-X(L) expression and caspase-3 and -7 activation.	Rosiglitazone	0-13	caspase 3	Homo sapiens	90-106	
15843042-9	2005	The proliferator-activated receptor-gamma (PPAR-gamma) agonists, rosiglitazone (RO), troglitazone (TR), and ciglitazone (CI), induced apoptosis in cells which was blocked by the addition of the PPAR-gamma antagonists, GW9662 and BADGE, via blocking of caspase 3 and PARP cleavage.	Rosiglitazone	65-78	caspase 3	Homo sapiens	252-261	
15843042-9	2005	The proliferator-activated receptor-gamma (PPAR-gamma) agonists, rosiglitazone (RO), troglitazone (TR), and ciglitazone (CI), induced apoptosis in cells which was blocked by the addition of the PPAR-gamma antagonists, GW9662 and BADGE, via blocking of caspase 3 and PARP cleavage.	Rosiglitazone	80-82	caspase 3	Homo sapiens	252-261	
31276504-0	2019	Rosiglitazone in the thawing medium improves mitochondrial function in stallion spermatozoa through regulating Akt phosphorylation and reduction of caspase 3.	Rosiglitazone	0-13	caspase 3	Homo sapiens	148-157	
31276504-8	2019	RESULTS: Rosiglitazone maintained Akt phosphorylation and reduced caspase 3 activation (p<0.01), both of which were prevented by incubation in the presence of the three inhibitors.	Rosiglitazone	9-22	caspase 3	Homo sapiens	66-75	
17532820-7	2007	Furthermore, the caspase-3 expression was determined by a immunocytochemical staining method before and after treatment with rosiglitazone and 15-d-PGJ2 for 48 h. The cell cycles were measured by flow cytometric analysis using propidium iodide (PI).	Rosiglitazone	125-138	caspase 3	Homo sapiens	17-26	
17532820-12	2007	Consistent with these results, the positivity rates of caspase-3 expression in cells treated with rosiglitazone or 15-d-PGJ2 increased significantly when compared with the control group.	Rosiglitazone	98-111	caspase 3	Homo sapiens	55-64	
12927354-6	2003	Furthermore, a PPARgamma ligand, rosiglitazone synergized the MEHP-induced caspase-3 activity.	Rosiglitazone	33-46	caspase 3	Homo sapiens	75-84	
26973118-4	2016	Here, we show that rosiglitazone reverses, via PPARgamma-dependent downregulation of caspase 3 and 9 activity, the Abeta-mediated decreases in hNSC cell viability.	Rosiglitazone	19-32	caspase 3	Homo sapiens	85-94	
28964868-4	2017	Here, we show that rosiglitazone treatment increases cell viability of hNSCs via downregulation of caspase 3 activity.	Rosiglitazone	19-32	caspase 3	Homo sapiens	99-108	
22129539-5	2011	Rosiglitazone decreased caspase-3 activity and cleavages of caspase-3, caspase-7, and parp.	Rosiglitazone	0-13	caspase 3	Homo sapiens	24-33	
22129539-5	2011	Rosiglitazone decreased caspase-3 activity and cleavages of caspase-3, caspase-7, and parp.	Rosiglitazone	0-13	caspase 3	Homo sapiens	60-69	
20227390-6	2010	In addition, pretreatment with a pan-caspase inhibitor, zVAD-fmk, attenuated the levels of caspase-3 activation and PARP cleavage in radiation-exposed cancer cells in combination with rosiglitazone pretreatment.	Rosiglitazone	184-197	caspase 3	Homo sapiens	91-100